Liver impairment study tests drug processing in 33 volunteers

NCT ID NCT06813781

Completed Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 1 study looked at how a single dose of the drug AZD5004 moves through the body in people with mild, moderate, or severe liver impairment compared to healthy volunteers. The goal was to measure drug levels and check safety. 33 adults aged 18-80 took part. The results will help guide future dosing for patients with liver issues.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AZD5004 (also known as ECC5004)
What this could lead to: If successful, this study could help doctors understand how to safely dose AZD5004 in patients with liver problems.
What could go wrong: This is a very early Phase 1 study with only 33 participants. It is designed to measure drug levels, not to treat any disease, so it may not lead to a treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATIC IMPAIRMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

liver disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATIC IMPAIRMENT

Contacts and locations

Locations

Research Site

Lake Forest, California, 92630, United States
Research Site

Rialto, California, 92377, United States
Research Site

Miami Lakes, Florida, 33014, United States
Research Site

Orlando, Florida, 32809, United States
Research Site

San Antonio, Texas, 78215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.